Global /China /Healthcare /Drug Manufacturers - General /600201
chevron_leftBack
Jinyu Bio-technology Co., Ltd. logo

Jinyu Bio-technology Co., Ltd.

600201
SSE: 600201 Delayed
14.59CNY 4%
2.16 USD
As of 14 June 2026, Jinyu Bio-technology Co., Ltd. has a market cap of $2.26B USD, ranking #6505 globally and #1523 in China. It ranks #513 in the Healthcare sector, and #197 in the Drug Manufacturers - General industry.
Global Rank
6505
Country Rank
1523
Sector Rank
513
Industry Rank
197
Key Stats
Market Cap
$2.26BUSD
15.33B CNY
Enterprise Value
$2.09BUSD
14.12B CNY
Revenue (TTM)
$195.85MUSD
1.33B CNY
EBITDA (TTM)
$26.26MUSD
177.72M CNY
Net Income (TTM)
$14.87MUSD
100.76M CNY
EBITDA Margin
13%
Profit Margin
7.6%
PE Ratio
146.0
Forward PE
58.5
PS Ratio
11.6
PB Ratio
2.7
EV/EBITDA
78.7
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Jing Zhang open_in_new
Employees
1,740
Founded
1992
Website
jinyu.com.cn open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
4% -1.9% 0.5% -25% 32% 107%

News

Loading...

Markets

Exchange Ticker Price
Shanghai Stock Exchange
MIC: XSHG
PRIMARY
600201
金宇生物技术股份有限公司 Class A
ISIN: CNE000000Y37
Shares Out.:
1.093B1 Shares Float: 819.986M2
TV:
SA:
YF:
GF:
BA:
MS:
14.59 CNY
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Jinyu Bio-technology Co., Ltd.

Jinyu Bio-technology Co., Ltd. manufacturing and sales of veterinary biological drugs in China. The company operates through three segments, such as veterinary biological products, veterinary chemical drugs, and traditional Chinese veterinary medicines. The company offers various pig vaccines, including combined porcine circovirus type 2 and mycoplasma pneumoniae, classical swine fever, combined transmissible gastroenteritis and porcine epidemic diarrhea, swine influenza bivalent, porcine reproductive and respiratory syndrome, pseudorabies thermo-stable, porcine reproductive and respiratory syndrome virus, porcine circovirus type 2 baculovirus vector, combined transmissible gastroenteritis and porcine epidemic diarrhea, swine foot and mouth disease bivalent, porcine parvovirus, pseudorabies, haemophilus parasuis trivalent, and porcine circovirus type 2 vaccines. It also provides ruminant vaccines, such as foot and mouth disease trivalent, bovine pasteurella multocida, combined bovine viral diarrhea disease and infectious bovine rhinotracheitis, brucella gene deletion, goat pox, brucellosi, brucellosis, foot and mouth disease bivalent and type O, clostridium chauvoei, lumpy skin disease, combined ovine infectious necrotic hepatitis and braxy, and caprine infectious pleuropneumonia, as well as combined ovine braxy, struck, lamb dysentery, enterotoxaemia, and black disease and clostridium botulinum toxonosis vaccines. In addition, the company offers avian vaccines; rabies vaccines; and PCR and Elisa diagnostic kits. Further, it is involved in manufacturing and sales of veterinary chemical preparations, chemical reagents and auxiliary agents, biological drug preparations, and advanced medical equipment and instruments; biotechnology development, transfer, and consulting services; import and export of goods and technology; and provision of property management services. The company was founded in 1992 and is headquartered in Hohhot, China.

Similar Companies

Industry: Drug Manufacturers - General (China)
Name
Market Cap diff.
PE
$53.85B
364.89B CNY
2K%
44.9
603259
$49.64B
336.36B CNY
2K%
17.2
$28.52B
223.48B HKD
1K%
35.7
$18.8B
147.32B HKD
731%
162.3
$16.51B
111.89B CNY
630%
-
9926
$16.01B
125.46B HKD
608%
-
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
34K%
38.1
JNJ
$547.28B
24K%
26.4
ABBV
$360.63B
16K%
97.4
$321.52B
256.25B CHF
14K%
19.9
AZN
$288.84B
215.59B GBP
13K%
27.6
NOVN
$274.65B
218.9B CHF
12K%
20.5
chevron_leftBack